Drug intelligence / Profile preview

BIL-221s

Development stage: Unknown
Lead developer: Biosceptre
Modality: Antibody-Based Therapeutics

Overview

BIL-221s is an investigational anticancer antibody being developed by Biosceptre to target a highly specific cancer-associated epitope that the company reports is present in at least 20 different tumor types.[3] It is one of Biosceptre’s pipeline products following proof-of-concept data with the related antibody BIL-010t and is being advanced into a phase I clinical trial in patients with a range of solid tumors in Australia, aiming to exploit selective tumor expression of its target to achieve antitumor activity with limited off‑tumor effects.[3]

Targets

nfP2X7 (Purinergic P2X7 receptor (non-functional form))

Beyond the preview

Go deeper on BIL-221s.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIL-221s.

Explore the full profile